Immunogen (IMGN) 10-K2022 FY Annual report

Filed: 1 Mar 23, 4:02pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: ANDA, arbitration, Assay, authorisation, bioavailability, biomarker, body, broken, buying, CAT, cdx, ceiling, channel, chemical, CHMP, chronically, clock, commodity, concomitant, confront, Congressional, constituting, Coordination, coordinator, copayment, CRh, debilitating, Decentralised, deny, difficulty, disagreement, DOJ, doubt, dry, Eisai, ELAHERE, ensuing, ESG, excise, exemplify, expedient, explanatory, explicitly, explore, extreme, eye, fist, formal, formalized, freight, FSS, Gilead, GmbH, hepatic, HIV, Iceland, incorrect, inflation, inflationary, infrastructure, inspire, ion, IRA, IVDR, justified, justify, laying, Lentini, Liechtenstein, Living, MAA, Magenta, magrolimab, mentorship, Mersana, MHRA, Michael, misrepresentation, mission, mix, moderate, moiety, narrow, neuropathy, NMPA, Norway, OIG, online, operationalizing, ophthalmologic, Ordinarily, pain, paragraph, PCHM, peripheral, photophobia, precaution, prevalence, PrimeVigilance, promptly, PVEK, rapporteur, recalculation, reclaim, regime, regional, reject, Renee, resell, resumption, Retail, RFI, routine, RTD, RxDx, sensitive, sensitivity, setback, shift, shortage, social, sound, specialty, stakeholder, statutorily, step, strain, strict, sublessee, subsidized, Sutro, Switzerland, team, teamwork, timeframe, Tissue, Tricare, uncollectible, unsatisfied, untitled, USA, variation, Vertex, viability, visibility, visual, weak, wellbeing

Removed: acquired, aforementioned, age, Akebia, America, area, ASH, ASU, attained, authorize, Bayer, biochemical, Biogen, Biomedicine, biopharmaceutical, Biotest, calendar, characterized, chosen, Clarifying, close, complementary, creating, death, decided, demonstrated, Dentistry, derived, discontinued, disputed, distributed, Doctor, doublet, Dr, drove, Eastern, emtansine, England, enrolling, estimable, eventually, evolved, exercisable, Fate, frequently, furniture, Fusion, Genzyme, globally, Harvard, Head, incomplete, influenced, institute, Interaction, investigational, JD, joining, Keryx, led, light, liquidate, master, mature, MD, mesothelin, Millennium, mutually, NHL, OBT, offsetting, oncology, outlicensing, partnering, PhD, planning, postdoctoral, Postemployment, practiced, published, pursuit, qualifying, ratably, recoverable, recruit, refinancing, remission, resignation, restructure, retention, retroactive, retrospective, Rochester, SA, Sanofi, School, segregated, selection, separating, shipment, Shire, Simplifying, soravtansine, sought, spent, superiority, Surrozen, survival, swap, Takeda, therefrom, Theresa, topic, transitioning, transplant, unamortized, University, unoccupied, vacate, Wingrove, write

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated IMGN transcripts

IMGN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 23

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)

Registration Statement (Form S-8 Nos. 333-138713, 333-147738, 333-155540, 333-170788, 333-185086, 333-215196, 333-225281, 333-225860, 333-235632, 333-235633, 333-251548, 333-253753, 333-258629, 333-258631, 333-266451 and 333-266452) of ImmunoGen, Inc., and

(2)

Registration Statement (Form S-3 No. 333-251502) of ImmunoGen, Inc.;

of our reports dated March 1, 2023, with respect to the consolidated financial statements of ImmunoGen, Inc. and the effectiveness of internal control over financial reporting of ImmunoGen, Inc. included in this Annual Report (Form 10-K) of ImmunoGen, Inc. for the year ended December 31, 2022.

/s/ Ernst & Young LLP

Boston, Massachusetts
March 1, 2023